Q3A_R2__Guideline.pdf - INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH

Q3A_R2__Guideline.pdf - INTERNATIONAL CONFERENCE ON...

This preview shows page 1 - 6 out of 15 pages.

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH H ARMONISED T RIPARTITE G UIDELINE I MPURITIES I N N EW D RUG S UBSTANCES Q3A(R2) Current Step 4 version dated 25 October 2006 This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.
Image of page 1
Q3A(R2) Document History First Codification History Date New Codification November 2005 Q3 Approval by the Steering Committee under Step 2 and release for public consultation. 15 March 1994 Q3A Q3A Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. Q3 was renamed Q3A. 30 March 1995 Q3A Q3A(R) Approval by the Steering Committee of the first Revision under Step 2 and release for public consultation. 7 October 1999 Q3A(R1) Q3A(R) Approval by the Steering Committee of the first Revision under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 6 February 2002 Q3A(R1) Current Step 4 version Q3A(R2) Approval by the Steering Committee of the revision of the Attachment 2 directly under Step 4 without further public consultation. 25 October 2006 Q3A(R2)
Image of page 2
I MPURITIES I N N EW D RUG S UBSTANCES ICH Harmonised Tripartite Guideline Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 7 February 2002, this guideline is recommended for adoption to the three regulatory parties to ICH. Attachment 2 has been revised on 25 October 2006. TABLE OF CONTENTS 1. PREAMBLE .............................................................................................................. 1 2. CLASSIFICATION OF IMPURITIES ..................................................................... 1 3. RATIONALE FOR THE REPORTING AND CONTROL OF IMPURITIES ...................................................................................................... 2 3.1 Organic Impurities ............................................................................................ 2 3.2 Inorganic Impurities .......................................................................................... 2 3.3 Solvents .............................................................................................................. 3 4. ANALYTICAL PROCEDURES ................................................................................ 3 5. REPORTING IMPURITY CONTENT OF BATCHES ............................................ 3 6. LISTING OF IMPURITIES IN SPECIFICATIONS ............................................... 4 7. QUALIFICATION OF IMPURITIES ....................................................................... 5 8. GLOSSARY ............................................................................................................... 6 ATTACHMENT 1 ............................................................................................................. 8 ATTACHMENT 2 ............................................................................................................. 9 ATTACHMENT 3 ........................................................................................................... 10 i
Image of page 3
Image of page 4
I MPURITIES I N N EW D RUG S UBSTANCES 1. PREAMBLE This document is intended to provide guidance for registration applications on the content and qualification of impurities in new drug substances produced by chemical syntheses and not previously registered in a region or member state. It is not intended to apply to new drug substances used during the clinical research stage of development. The following types of drug substances are not covered in this guideline: biological/biotechnological, peptide, oligonucleotide, radiopharmaceutical, fermentation product and semi-synthetic products derived therefrom, herbal products, and crude products of animal or plant origin.
Image of page 5
Image of page 6

You've reached the end of your free preview.

Want to read all 15 pages?

  • Fall '16
  • Henry
  • Accounting, ........., Drug development, New chemical entity, New Drug Substances

What students are saying

  • Left Quote Icon

    As a current student on this bumpy collegiate pathway, I stumbled upon Course Hero, where I can find study resources for nearly all my courses, get online help from tutors 24/7, and even share my old projects, papers, and lecture notes with other students.

    Student Picture

    Kiran Temple University Fox School of Business ‘17, Course Hero Intern

  • Left Quote Icon

    I cannot even describe how much Course Hero helped me this summer. It’s truly become something I can always rely on and help me. In the end, I was not only able to survive summer classes, but I was able to thrive thanks to Course Hero.

    Student Picture

    Dana University of Pennsylvania ‘17, Course Hero Intern

  • Left Quote Icon

    The ability to access any university’s resources through Course Hero proved invaluable in my case. I was behind on Tulane coursework and actually used UCLA’s materials to help me move forward and get everything together on time.

    Student Picture

    Jill Tulane University ‘16, Course Hero Intern

Stuck? We have tutors online 24/7 who can help you get unstuck.
A+ icon
Ask Expert Tutors You can ask You can ask You can ask (will expire )
Answers in as fast as 15 minutes